Physician profile
Thomas B Taylor
NPI 1700866621
$19,145.42
in general payments reported to CMS, 2019-2025
68 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,993 · 2020: $2,956 · 2021: $3,385 · 2022: $2,729 · 2023: $2,505 · 2024: $2,418 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,082.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,227.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $1,803.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,737.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,324.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,297.41 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,148.21 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,046.52 | 2019-2025 | |
| Amgen INC. | $942.53 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $881.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $511.82 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $452.01 | 2021-2025 | |
| Astellas Pharma US INC | $395.87 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $386.20 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $368.75 | 2019-2025 | |
| Antares Pharma, INC. | $337.70 | 2019-2025 | Xyosted, Nocdurna, Tlando |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.